IRCT20200105046010N19
Not yet recruiting
未知
Pharmacokinetic assessments of Fampridine tablet 10mg extended release in comparison with brand drugs FAMPYRA
Pharan shimi Pharmaceutical Company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- The aim of this study is evaluation of bioequivalence of test and reference drugs and the study will one by healthy volunteers.
- Sponsor
- Pharan shimi Pharmaceutical Company
- Enrollment
- 24
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General health
- •Body Mass Index (BMI) between 18\-28
- •Informed consent
- •Age between 18\-60
- •Both male and female
Exclusion Criteria
- •Alcohol \& Drug addiction
- •Hypersensitivity to the drug
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Fampridine effect on Parkinson disease symptomsParkinson disease.Parkinson's diseaseIRCT20230905059361N1Shahre-kord University of Medical Sciences62
Recruiting
Not Applicable
In-vivo Bioequivalence Test of YUNIMIDE® tablet with brand drugs (VIMPAT®200mg UCB Pharma, Belgium)IRCT20200105046010N18Tabriz University of Medical Sciences24
Not yet recruiting
Not Applicable
In vivo study of famotidine tablet 40 mgIRCT20230222057495N1Aria Pharmaceutical Company24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Neotadin® tablet with brand drugs (AERIUS® 5mg, FC Schering-Plough Belgium).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Desloratadine studied..IRCT20200105046010N21ABIDI Pharmaceutical Company24
Active, not recruiting
Not Applicable
A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma.EUCTR2009-017099-25-GBOriel Therapeutics Inc30